These are the 25 stocks to bet against on a successful COVID-19 vaccine, according to JPMorgan
- With a successful COVID-19 vaccine on the horizon, some stocks may fare better than others.
- According to JPMorgan, investors should look to bet against a handful of stocks that have experienced increased momentum in their business amid the COVID-19 pandemic.
- Once a successful COVID vaccine is distributed and administered, it could lead to a slowdown in growth for a number of businesses as a return to normal activity ensues.
- Here are 25 stocks traders should bet against once a successful COVID-19 vaccine is disbursed, according to JPMorgan.
- Visit Business Insider's homepage for more stories.
The development of a successful COVID-19 vaccine could have wide-ranging implications on a basket of stocks that saw a surge in growth amid the pandemic.
That's according to a Friday note from JPMorgan, which put together a list of 25 stocks traders should bet against once a COVID-19 vaccine is distributed and administered to the population.
"This is a list of stocks that are in the upper echelon of Momentum and have crowded positioning, that could see the second derivative of their profit growth decrease as consumer/corporate activity normalizes," JPMorgan explained.
On the flip side, Goldman Sachs offered six stocks on Friday that could benefit from the distribution and administration of a successful COVID-19 vaccine.
The JPMorgan basket of stocks should be viewed as a tactical opportunity to express a bearish view on the catalyst of a COVID-19 vaccine, and should not be viewed as a fundamental call on the company.
Here are 25 stocks traders should bet against once a successful COVID-19 vaccine is disbursed, according to JPMorgan.
YTD Performance: 2190%
YTD Performance: 654%
YTD Performance: 887%
YTD Performance: 583%
YTD Performance: 338%
YTD Performance: 250%
YTD Performance: 206%
YTD Performance: 199%
YTD Performance: 171%
YTD Performance: 167%
YTD Performance: 141%
YTD Performance: 127%
YTD Performance: 95%
YTD Performance: 81%
YTD Performance: 66%
YTD Performance: 63%
YTD Performance: 47%
YTD Performance: 47%
YTD Performance: 40%
YTD Performance: 38%
YTD Performance: 38%
YTD Performance: 29%
YTD Performance: 29%
YTD Performance: 26%
Performance since IPO: 25%